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Cardiovascular disease (CVD) is the leading cause of morbidity and mortality. 
Coronary heart disease (CHD) occurs in women a decade later compared with men 
and the gap between men and women narrows with advancing age. In addition, cardio-
vascular mortality declines in men but not in women. Coronary heart disease (CHD) 
accounts for the majority of CVD deaths in women.
The spectrum of CVD risk in women (10-year absolute CHD risk) varies from 
high (>20%) for women with established CHD, cerebrovascular disease, peripheral 
artery disease, abdominal aortic aneurysm, diabetes and chronic kidney disease to 
intermediate risk (10-20%) for women with multiple risk factors, markedly elevated 
levels of a single risk factor, metabolic syndrome, first degree relatives with early onset 
of CVD and subclinical CVD (e.g. coronary calcification) and low risk (<10%), mainly 
for women with 1 or no risk factors. Hypertriglygeridemia, low HDL cholesterol, dia-
betes and the metabolic syndrome are more potent risk factors for CHD in women 
compared with men. High-sensitivity C-reactive protein (CRP) and anemia are other 
novel risk factors for women and hypoestrogenemia of hypothalamic origin may be 
a risk factor for pre-menopausal women and one possible cause for the increased 
mortality in young women versus age-matched men in acute myocardial infarction 
(MI) as well as post bypass surgery. For prevention aspirin, â-blockers, angiotensin 
converting enzyme (ACE) inhibitors and statins are indicated for higher risk women, 
whereas for lower risk healthy life style changes are recommended.
Women may present with atypical symptoms; the exertional component is the 
most important gender-related difference in symptom predictive accuracy. In terms 
of diagnosis, the exercise stress test has lower sensitivity and specificity in women as 
compared to men (60-70% vs 80%), in part due to their lower CHD prevalence and 
their inability to achieve maximal workload. Symptomatic women with at least interme-
diate pretest risk, with a normal resting ECG and capable of maximal exercise should 
undergo exercise testing. Symptomatic women with at least intermediate pretest risk 
with abnormal resting ECG or maximal exercise capacity <5METS should be evalu-
ated with SPECT imaging with pharmacological stress, with a mean sensitivity of 80%. 
Stress echocardiography is an alternative with equal sensitivity but higher specificity, 
with obesity and lung disease being the main limitations. Because of older age and 
higher risk profile, differences in symptoms and pain perception, lower predictive ac-
curacy of the noninvasive tests and a slightly higher risk of adverse outcome following 
revascularization, women are referred to coronary angiography less often than men. 
However, once they are catheterized, they are treated similarly to men.
Women present more often with angina and less often with acute myocardial 
infarction (AMI) and in acute coronary syndromes (ACS) they present with unstable 
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angina rather than non-ST elevation MI (NSTEMI). In ad-
dition, in ACS there is a differential expression of cardiac 
biomarkers; men have higher creatine kinase MB and tropo-
nins, whereas women have elevated CRP and brain natriuretic 
peptide (BNP). Sudden death in young women is associated 
with plaque erosion rather than plaque rupture that occurs 
in older women and all men. Women present more often with 
congestive heart failure although they have better left ventricu-
lar function compared to men and they are more symptomatic 
for any given extent of coronary disease. In addition, almost 
50% of women, evaluated for suspected ischemia, do not have 
obstructive coronary artery disease; this may be associated 
with microvascular dysfunction and more diffuse disease.
In ACS, only high risk women benefit from the invasive 
approach, whereas in ST-elevation MI (STEMI) primary 
percutaneous coronary intervention (PCI) is the treatment 
of choice if available with door to balloon time <90 min. In 
cardiogenic shock the benefit from revascularization is similar 
to men. Women, because of age, comorbidities and smaller 
body surface area, have worse clinical outcome following 
elective PCI or coronary artery bypass grafting (CABG) 
surgery compared to men but this difference has been very 
much decreased over the years. Drug-eluting stents are equally 
effective in women as are minimal access approaches in car-
diac surgery. Despite smaller vessels and higher incidence of 
diabetes, women have similar rates of target lesion revascu-
larization (TLR) post-PCI. Vascular complications are 1.5-4 
times more frequent in women.
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